Single, large trial in HIV risk reduction and vaginal microbicides acceptable -- joint cmte..
This article was originally published in The Tan Sheet
VAGINAL MICROBICIDE HIV RISK REDUCTION COULD BE TESTED IN SINGLE, LARGE TRIAL, members of FDA's Nonprescription Drugs, Reproductive Health Drugs, Anti-Infective Drugs and Antiviral Drugs Advisory Committees agreed Nov. 21 at a joint meeting in Gaithersburg, Md. As envisioned by the committee, such a study would evaluate the safety and efficacy of vaginal microbicides in preventing HIV transmission and might include data from both domestic study sites and international high-risk groups.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC